$1.19
Value $127M
MaxCytevsThermo Fisher Scientific
MXCT and TMO stock compared: price, dividend, valuation and results, from SEC filings.
+0.00%
$700.22
Value $260B
MaxCyte (MXCT) has a market value of $127M and Thermo Fisher Scientific (TMO) $260B. Over the last year, with dividends, MXCT moved -24.7% and TMO +19.5%. Dividend yield: MXCT none, TMO 0.26%.
At a glance
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
MXCT$127M
TMO$260B
TMO is 2,046 times MXCT
Revenue, 12 months
MXCT$34M
TMO$47.4B
TMO is 1,378 times MXCT
Net income, 12 months
MXCT-$28M
TMO$7.1B
Operating margin
MXCT-98.0%
TMO17.9%
115.9 points apart
ROIC
MXCT-16.0%
TMO8.2%
24.2 points apart
P/E
MXCT–
TMO36.8
Dividend yield
MXCT0.0%
TMO0.3%
0.3 points apart
5-year return
MXCT-90.5%
TMO+11.8%
102.3 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
The price over time
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
MXCT-90.5%
TMO+11.8%
| Period | MXCTWith dividends | TMOWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | -24.7%Price -24.7% | +19.5%Price +19.1% |
| 3 years since November 13, 2023 | -65.8%-30.1% a yearPrice -65.8% | +58.8%+16.7% a yearPrice +57.3% |
| 5 years since November 12, 2021 | -90.5%-37.6% a yearPrice -90.5% | +11.8%+2.3% a yearPrice +10.2% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
Every figure
As on each company's page. A description, not a recommendation: no one figure says which is better.
MXCTMaxCyteTMOThermo Fisher Scientific
Valuation
MXCTTMO| Price | $1.19 | $700.22 |
|---|---|---|
| Market value | $127M | $260B |
| Enterprise value (EV) | $26M | $295B |
| P/E | – | 36.8 |
| P/E, 5-year median | – | 32.7 |
| P/B | 0.8 | 4.8 |
| EV/EBIT | – | 34.9 |
| Free cash flow yield | – | 2.9% |
Results and growth
MXCTTMO| Revenue, 12 months | $34M | $47.4B |
|---|---|---|
| Net income, 12 months | -$28M | $7.1B |
| Free cash flow, 12 months | -$21M | $7.6B |
| Earnings per share, 12 months | -$0.26 | $18.96 |
| Revenue growth, year on year | -14.5% | 3.9% |
| Revenue growth a year, past | +4.8%over 5 years | +6.7%over 5 years |
| EPS growth a year, past | – | +2.1%over 5 years |
Margins and returns on capital
MXCTTMO| Gross margin | 81.0% | – |
|---|---|---|
| Operating margin | -98.0% | 17.9% |
| Net margin | -81.4% | 14.9% |
| ROIC | -16.0% | 8.2% |
| ROE | -16.9% | 13.4% |
Balance sheet
MXCTTMO| Cash | $101M | $6.1B |
|---|---|---|
| Total debt | $17M | $41.4B |
| Net debt / EBITDA | – | 3.7 |
| Interest cover | – | 5.5× |
Dividends and buybacks
MXCTTMO| Dividend yield | – | 0.3% |
|---|---|---|
| Dividend per share, 12 months | – | $1.84 |
| Dividend growth a year, past | – | +14.3%over 5 years |
| Buyback yield | – | 1.2% |
| Shareholder yield | – | 1.4% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
Which is bigger, MaxCyte or Thermo Fisher Scientific?
By market value, Thermo Fisher Scientific ($260B) is about 2,045.5 times MaxCyte ($127M), at today's prices.
How did MXCT and TMO stock do over the last 5 years?
Since November 12, 2021, MXCT's price moved -90.5% and TMO's +10.2%. With dividends: MXCT -90.5% (-37.6% a year), TMO +11.8% (+2.3% a year). Past returns do not predict future ones.
Which pays the higher dividend, MXCT or TMO?
The dividend yield at today's price is none for MaxCyte and 0.26% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.
Which has the higher profit margins, MaxCyte or Thermo Fisher Scientific?
Over the last twelve months, the net margin was -81.4% for MaxCyte and 14.9% for Thermo Fisher Scientific, and the operating margin -98.0% and 17.9%. Revenue was $34M and $47.4B.
Which is the better investment, MaxCyte or Thermo Fisher Scientific?
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
Other comparisons
With each of the two, and with the largest in its sector.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.
Descriptive data from SEC filings and market prices.